Arvinas, Inc. announced that its Chief Medical Officer, Noah Berkowitz, M.D., Ph.D., will depart from the company on July 3, 2026. The company has initiated a search for a replacement. Arvinas, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted protein degradation therapies.

Arvinas, Inc. received HSR Clearance for its license agreement with Rigel Pharmaceuticals, Inc. for VEPPANU (vepdegestrant) rights, resulting in an aggregate upfront payment of $70.0 million to Arvinas and Pfizer. The Company and Pfizer are also eligible for an additional $15.0 million upon completion of transition activities and up to $320.0 million in contingent milestone and royalty payments. Arvinas, Inc. is a biotechnology company focused on protein degradation technologies.